Pulse 2.0
Cover art for Marrow Therapeutics Launches With $173 Million

Marrow Therapeutics Launches With $173 Million

Marrow Therapeutics secures $173 million for bone marrow-targeted medicines to treat blood disorders.

By ·

Nov 17, 2026

9 cards · 1m 40s · tap to begin

From · · · 1m 40s

Marrow Therapeutics Launches With $173 Million

Marrow Therapeutics secures $173 million for bone marrow-targeted medicines to treat blood disorders.

In brief

Marrow Therapeutics secures $173 million for bone marrow-targeted medicines to treat blood disorders. Marrow Therapeutics received $173 million in funding to develop genetic medicines for severe blood and bone marrow disorders. Originally reported by Pulse 2.0.

Funding Announcement

Marrow Therapeutics has launched with $173 million in combined Series A and Series B funding to develop genetic medicines for severe blood and bone marrow disorders.

Funding Breakdown

The $53 million Series A round was co-led by Scion Life Sciences and venBio, with OrbiMed leading a subsequent $120 million Series B financing.

Investors

All Series A investors participated in the Series B alongside RTW Investments, Surveyor Capital, Opaleye, NEXTBio Capital, Affinity Advisors, KKR, Spruce Street Capital, and Columbia Threadneedle Investments.

Company Background

Scion Life Sciences founded Marrow Therapeutics, which is headquartered in Watertown, Massachusetts.

Bone Marrow-Targeting Platform

Marrow is developing engineered antibodies that target the transferrin receptor, also known as TfR1, in bone marrow.

Platform Purpose

The company’s Transferrin Antibody Bioconjugate platform delivers therapeutic payloads directly to bone marrow cells for multiple hematologic and bone marrow diseases.

Lead Program Targets Two Blood Disorders

Marrow’s lead candidate, MAR-101, is being developed for sickle cell disease and beta thalassemia through studies to support an investigational new drug application.

Therapeutic Strategy

MAR-101 decreases BCL11A and reactivates fetal hemoglobin production to treat sickle cell disease and beta thalassemia.

Pipeline in a Product

Marrow uses a single therapeutic approach for both conditions, calling it a 'pipeline in a product' strategy to validate the platform across multiple diseases.

The headline

Marrow Therapeutics received $173 million in funding to develop genetic medicines for severe blood and bone marrow disorders.

Read the original on Pulse 2.0

Read the TL;DR — this story on one card.

How we make summaries

React

Sign in to react and comment.

Comments (0)

Life is short. Keep it sweet. Respect others' opinions and be kind!

    Recommended next

    More decks on marrow therapeutics and related topics.